-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

Benzinga·05/09/2025 22:40:37
Listen to the news
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $28 to $25.